Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Yan, Max ^a,b   Xu, Huiling ^c,d   Waddell, Nic ^e   Shield Artin, Kristy ^f   Haviv, Izhak ^f   McKay, Michael J ^c,g   Fox, Stephen B ^c  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF QUEENSLAND   (Australia)

^f BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^g UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; COHESIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR ALPHA; HORMONE; MESSENGER RNA; MICRORNA; MICRORNA 299 5P; PROTEIN RAD21; UNCLASSIFIED DRUG; BRCA1 PROTEIN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN; MIRN299 MICRORNA, HUMAN; NUCLEAR PROTEIN; PHOSPHOPROTEIN; RAD21 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; BRCA2 GENE; BRCAX GENE; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER HORMONE THERAPY; CANCER PROGNOSIS; CANCER SIZE; CANCER SURVIVAL; COPY NUMBER VARIATION; DISEASE SPECIFIC SURVIVAL; FAMILIAL CANCER; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENOMIC INSTABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RAD21 GENE; RECURRENCE FREE SURVIVAL; SURVIVAL TIME; TREATMENT OUTCOME; BREAST TUMOR; COHORT ANALYSIS; GENE EXPRESSION REGULATION; GENETICS; HETEROZYGOTE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY; PEDIGREE; PREDICTIVE VALUE; PROGNOSIS; REPRODUCIBILITY;

BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOMIC INSTABILITY; HETEROZYGOTE; HUMANS; MICRORNAS; MIDDLE AGED; NUCLEAR PROTEINS; PEDIGREE; PHOSPHOPROTEINS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 84860138332     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3176     Document Type: Article

References (44)

1. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Sanchez L, Rivas C, Benitez J. Immunohistochemical characteristics defined by tissue microarray of hereditary breast cancer not attributable to BRCA1 or BRCA2 mutations: differences from breast carcinomas arising in BRCA1 and BRCA2 mutation carriers. Clin Cancer Res 2003, 9:3606-3614.
2. Lakhani SR, Gusterson BA, Jacquemier J, Sloane JP, Anderson TJ, van de Vijver MJ, Venter D, Freeman A, Antoniou A, McGuffog L, Smyth E, Steel CM, Haites N, Scott RJ, Goldgar D, Neuhausen S, Daly PA, Ormiston W, McManus R, Scherneck S, Ponder BA, Futreal PA, Peto J, Stoppa-Lyonnet D, Bignon YJ, Stratton MR. The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. Clin Cancer Res 2000, 6:782-789.
3. Palacios J, Honrado E, Osorio A, Cazorla A, Sarrio D, Barroso A, Rodriguez S, Cigudosa JC, Diez O, Alonso C, Lerma E, Dopazo J, Rivas C, Benitez J. Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers. Breast Cancer Res Treat 2005, 90:5-14. 10.1007/s10549-004-1536-0, 15770521.
4. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95:1482-1485. 10.1093/jnci/djg050, 14519755.
5. Lakhani SR, Reis-Filho JS, Fulford L, Penault-Llorca F, van der Vijver M, Parry S, Bishop T, Benitez J, Rivas C, Bignon YJ, Chang-Claude J, Hamann U, Cornelisse CJ, Devilee P, Beckmann MW, Nestle-Kramling C, Daly PA, Haites N, Varley J, Lalloo S, Radice P, Scherneck S, Sobol H, Jacquemier J, Wagner T, Peto J, Stratton MR, McGuffog L, Easton DF. Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype. Clin Cancer Res 2005, 11:5175-5180. 10.1158/1078-0432.CCR-04-2424, 16033833.
6. Armes JE, Egan AJ, Southey MC, Dite GS, McCredie MR, Giles GG, Hopper JL, Venter DJ. The histologic phenotypes of breast carcinoma occurring before age 40 years in women with and without BRCA1 or BRCA2 germline mutations: a population-based study. Cancer 1998, 83:2335-2345. 10.1002/(SICI)1097-0142(19981201)83:11<2335::AID-CNCR13>3.0.CO;2-N, 9840533.
7. Nasmyth K, Haering CH. Cohesin: its roles and mechanisms. Annu Rev Genet 2009, 43:525-558. 10.1146/annurev-genet-102108-134233, 19886810.
8. Peters JM, Tedeschi A, Schmitz J. The cohesin complex and its roles in chromosome biology. Genes Dev 2008, 22:3089-3114. 10.1101/gad.1724308, 19056890.
9. Schmidt D, Schwalie PC, Ross-Innes CS, Hurtado A, Brown GD, Carroll JS, Flicek P, Odom DT. A CTCF-independent role for cohesin in tissue-specific transcription. Genome Res 2010, 20:578-588. 10.1101/gr.100479.109, 2860160, 20219941.
10. Rollins RA, Korom M, Aulner N, Martens A, Dorsett D. Drosophila nipped-B protein supports sister chromatid cohesion and opposes the stromalin/Scc3 cohesion factor to facilitate long-range activation of the cut gene. Mol Cell Biol 2004, 24:3100-3111. 10.1128/MCB.24.8.3100-3111.2004, 381657, 15060134.
11. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, Barrette T, Pandey A, Chinnaiyan AM. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004, 101:9309-9314. 10.1073/pnas.0401994101, 438973, 15184677.
12. Oishi Y, Nagasaki K, Miyata S, Matsuura M, Nishimura S, Akiyama F, Iwai T, Miki Y. Functional pathway characterized by gene expression analysis of supraclavicular lymph node metastasis-positive breast cancer. J Hum Genet 2007, 52:271-279. 10.1007/s10038-007-0111-z, 17285241.
13. Xu X, Yan M, Natrajan R, Yan Y, Swagemakers S, Tomaszewski JM, Verschoor S, Millar EKA, van der Spek P, Reis-Filho J, Ramsay RG, O'Toole SA, McNeil CM, Sutherland RL, MacKay MJ, Fox SB. Enhanced Rad21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers. Breast Cancer Res 2011, 32:13 R9.
14. Atienza JM, Roth RB, Rosette C, Smylie KJ, Kammerer S, Rehbock J, Ekblom J, Denissenko MF. Suppression of RAD21 gene expression decreases cell growth and enhances cytotoxicity of etoposide and bleomycin in human breast cancer cells. Mol Cancer Ther 2005, 4:361-368.
15. Yan M, Rayoo M, Takano EA, Fox SB. Nuclear and cytoplasmic expressions of ERbeta1 and ERbeta2 are predictive of response to therapy and alters prognosis in familial breast cancers. Breast Cancer Res Treat 2011, 126:395-405. 10.1007/s10549-010-0941-9, 20490651.
16. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol 2005, 23:9067-9072. 10.1200/JCO.2004.01.0454, 16172462.
17. Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, Enrolment of Families and Data Collection. , http://www.kconfab.org/Index.shtml
18. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374. 10.1158/1078-0432.CCR-04-0220, 15328174.
19. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R. Immunohistochemical detection of steroid receptors in breast cancer: a working protocol; UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 2000, 53:634-635. 10.1136/jcp.53.8.634, 1762930, 11002770.
20. Waddell N, Arnold J, Cocciardi S, da Silva L, Marsh A, Riley J, Johnstone CN, Orloff M, Assie G, Eng C, Reid L, Keith P, Yan M, Fox S, Devilee P, Godwin AK, Hogervorst FB, Couch F, Grimmond S, Flanagan JM, Khanna K, Simpson PT, Lakhani SR, Chenevix-Trench G. Subtypes of familial breast tumours revealed by expression and copy number profiling. Breast Cancer Res Treat 2010, 123:661-677. 10.1007/s10549-009-0653-1, 19960244.
21. Lingjaerde OC, Baumbusch LO, Liestol K, Glad IK, Borresen-Dale AL. CGH-Explorer: a program for analysis of array-CGH data. Bioinformatics 2005, 21:821-822. 10.1093/bioinformatics/bti113, 15531610.
22. Assie G, LaFramboise T, Platzer P, Bertherat J, Stratakis CA, Eng C. SNP arrays in heterogeneous tissue: highly accurate collection of both germline and somatic genetic information from unpaired single tumor samples. Am J Hum Genet 2008, 82:903-915. 10.1016/j.ajhg.2008.01.012, 2427213, 18355774.
23. Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNA associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res 2011, 71:5635-5645. 10.1158/0008-5472.CAN-11-0489, 21737487.
24. Chen J, Lozach J, Garcia EW, Barnes B, Luo S, Mikoulitch I, Zhou L, Schroth G, Fan JB. Highly sensitive and specific microRNA expression profiling using BeadArray technology. Nucleic Acids Res 2008, 36:e87. 10.1093/nar/gkn387, 2504321, 18579563.
25. Pradervand S, Weber J, Thomas J, Bueno M, Wirapati P, Lefort K, Dotto GP, Harshman K. Impact of normalization on miRNA microarray expression profiling. RNA (New York) 2009, 15:493-501.
26. Pradervand S, Weber J, Lemoine F, Consales F, Paillusson A, Dupasquier M, Thomas J, Richter H, Kaessmann H, Beaudoing E, Hagenbuchle O, Harshman K. Concordance among digital gene expression, microarrays, and qPCR when measuring differential expression of microRNAs. BioTechniques 2010, 48:219-222. 10.2144/000113367, 20359303.
27. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008, 36:D154-158. 10.1093/nar/gkn221, 2238936, 17991681.
28. Microcosm Targets. , http://www.ebi.ac.uk/enright-srv/microcosm/cgi-bin/targets/v5/search.pl
29. Tirkkonen M, Kainu T, Loman N, Johannsson OT, Olsson H, Barkardottir RB, Kallioniemi OP, Borg A. Somatic genetic alterations in BRCA2-associated and sporadic male breast cancer. Genes Chromosomes Cancer 1999, 24:56-61. 10.1002/(SICI)1098-2264(199901)24:1<56::AID-GCC8>3.0.CO;2-X, 9892109.
30. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007, 8:735-748.
31. Chen F, Kamradt M, Mulcahy M, Byun Y, Xu H, McKay MJ, Cryns VL. Caspase proteolysis of the cohesin component RAD21 promotes apoptosis. J Biol Chem 2002, 277:16775-16781. 10.1074/jbc.M201322200, 11875078.
32. Martin SA, Ouchi T. BRCA1 phosphorylation regulates caspase-3 activation in UV-induced apoptosis. Cancer Res 2005, 65:10657-10662. 10.1158/0008-5472.CAN-05-2087, 16322207.
33. Xu H, Tomaszewski JM, McKay MJ. Can corruption of chromosome cohesion create a conduit to cancer?. Nat Rev Cancer 2011, 11:199-210. 10.1038/nrc3018, 21326324.
34. Dorsett D. Cohesin: genomic insights into controlling gene transcription and development. Curr Opin Genet Dev 2011, 21:199-206. 10.1016/j.gde.2011.01.018, 3070859, 21324671.
35. Mendes-Pereira AM, Sims D, Dexter T, Fenwick K, Assiotis I, Kozarewa I, Mitsopoulos C, Hakas J, Zvelebil M, Lord CJ, Ashworth A. Genome-wide functional screen identifies a compendium of genes affecting sensitivity to tamoxifen. Proc Natl Acad Sci USA 2012, 109:2730-2735. 10.1073/pnas.1018872108, 21482774.
36. van Agthoven T, Sieuwerts AM, Meijer D, Meijer-van Gelder ME, van Agthoven TL, Sarwari R, Sleijfer S, Foekens JA, Dorssers LC. Selective recruitment of breast cancer anti-estrogen resistance genes and relevance for breast cancer progression and tamoxifen therapy response. Endocr Relat Cancer 2010, 17:215-230. 10.1677/ERC-09-0062, 19966015.
37. Schuetz CS, Bonin M, Clare SE, Nieselt K, Sotlar K, Walter M, Fehm T, Solomayer E, Riess O, Wallwiener D, Kurek R, Neubauer HJ. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis. Cancer Res 2006, 66:5278-5286. 10.1158/0008-5472.CAN-05-4610, 16707453.
38. van Schooneveld E, Wouters M, Van der Auwera I, Peeters D, Huget P, van Dam PA, Vermeulen PB, Van Laere SJ, Dirix LY. Detection of circulating miRNAs in serum from patients with breast cancer and their association with the presence of metastatic disease. J Clin Oncol 2011, 29:abstr 10506.
39. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008, 68:2094-2105. 10.1158/0008-5472.CAN-07-5194, 18381414.
40. Shevde LA, Metge BJ, Mitra A, Xi Y, Ju J, King JA, Samant RS. Spheroid-forming subpopulation of breast cancer cells demonstrates vasculogenic mimicry via hsa-miR-299-5p regulated de novo expression of osteopontin. J Cell Mol Med 2010, 14:1693-1706.
41. Hahnel A, Wichmann H, Kappler M, Kotzsch M, Vordermark D, Taubert H, Bache M. Effects of osteopontin inhibition on radiosensitivity of MDA-MB-231 breast cancer cells. Radiat Oncol 2012, 5:82.
42. Pang H, Cai L, Yang Y, Chen X, Sui G, Zhao C. Knockdown of osteopontin chemosensitizes MDA-MB-231 cells to cyclophosphamide by enhancing apoptosis through activating p38 MAPK pathway. Cancer Biother Radiopharm 2011, 26:165-173. 10.1089/cbr.2010.0838, 21539449.
43. Alli E, Sharma VB, Sunderesakumar P, Ford JM. Defective repair of oxidative DNA damage in triple-negative breast cancer confers sensitivity to inhibition of poly(ADP-ribose) polymerase. Cancer Res 2009, 69:3589-3596. 10.1158/0008-5472.CAN-08-4016, 2681413, 19351835.
44. Ashworth A. A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair. J Clin Oncol 2008, 26:3785-3790. 10.1200/JCO.2008.16.0812, 18591545.